Phase I Study of Novel Radioenhancer NBTXR3 Activated by Radiotherapy in Cisplatin-Ineligible Locally Advanced HNSCC Patients

C Le Tourneau,V Calugaru, Z Takacsi-Nagy, X Liem, Z Papai, J Fijuth,V Moreno Garcia,I Brana Garcia, S Salas, G Poissonnet,E Calvo, B Doger, O Choussy,X Mirabel, S Krhili, K Bernois, N Fakhry,S Wong Hee Kam,E Borcoman,C Hoffmann

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS（2021）

引用 0|浏览0

暂无评分

摘要

NBTXR3 intratumoral administration followed by IMRT may represent an option in elderly in elderly patients or patients with multiple comorbidities with LA-HNSCC who have limited therapeutic options. NBTXR3 activated by RT showed promising anti-tumor efficacy, supporting further evaluation in a phase III randomized trial.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要